title: Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
abstract: OBJECTIVE
  The objective of this study was to identify the factors influencing trough teicoplanin concentrations (C(min)), to investigate the relationship between teicoplanin C(min) with efficacy and safety, and to determine a target therapeutic concentration.
  
  
  METHODS
  An analysis was performed on 95 serum concentrations from 50 patients with gram-positive infections who received teicoplanin treatment. Teicoplanin serum concentrations were measured by high-performance liquid chromatography. Univariate and multivariable analysis were performed to investigate the effect of independent variables on teicoplanin C(min). A logistic regression analysis was used to determine the relationship between teicoplanin C(min) and efficacy and safety.
  
  
  RESULTS
  Teicoplanin therapy was effective in 74.0% (37/50) of patients, and 10.0% (5/50) of patients exhibited signs of adverse events. Using multivariable linear regression, two covariates were found to be a significant effect on teicoplanin C(min): dosage (mg/kg), and creatinine clearance rate (CL(cr). There was no covariate that has a significant impact on the safety of teicoplanin and only teicoplanin C(min) has a significant impact on the efficacy of treatment in the logistics regression. The logistics regression analysis showed that teicoplanin C(min) of 10 mg/L was associated with a 79.4% probability of success response.
  
  
  CONCLUSIONS
  This study highlighted that teicoplanin C(min) was strongly influenced by the values of dosage (mg/kg) and CL(cr) and the teicoplanin C(min) range of 10 - 20 mg/L was identified as the therapeutic target with optimum clinical efficacy and safety.
authors.forename: Taotao
authors.initials: T
authors.lastname: Wang
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.forename: Sasa
authors.initials: S
authors.lastname: Hu
authors.forename: Jiao
authors.initials: J
authors.lastname: Xie
authors.forename: Jin'e
authors.initials: J
authors.lastname: Lei
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Zheng
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Xing
authors.forename: Yalin
authors.initials: Y
authors.lastname: Dong
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D002681:China; D002851:Chromatography, High Pressure Liquid; D054796:Drug Dosage Calculations; D016903:Drug Monitoring; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D061214:Patient Safety; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D017334:Teicoplanin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin